Description
Anti-Human C5 (Ravulizumab)-Fc silent antibody is derived from clone Vilobelimab, which is a Chimeric monoclonal antibody targeting the C5. And it is intended for the research of COVID-19.
Research Area
Cell Biology, Immunology,
Antigen Distribution
Biased expression in liver (RPKM 85.9) and lung (RPKM 3.7).
Disease
severe pneumonia or acute respiratory distress syndrome
Application Notes
The use of diluent depends on the detection system used. It is recommended that users test reagents and determine their own optimal dilution.
Handling Advice
This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.
Storage Instructions
Product should be stored at -80°C. Repeated freeze and thaw cycles will cause loss of activity. Use product within 24 hours after thawing and keep on ice. Remainder amounts should be aliquoted and immediately re-freezed for future use. Aliquots should never be thawed more than once. Under recommended storage conditions, product is stable for at least one year.
Background
This gene encodes a component of the complement system, a part of the innate immune system that plays an important role in inflammation, host homeostasis, and host defense against pathogens. The encoded preproprotein is proteolytically processed to generate multiple protein products, including the C5 alpha chain, C5 beta chain, C5a anaphylatoxin and C5b. The C5 protein is comprised of the C5 alpha and beta chains, which are linked by a disulfide bridge. Cleavage of the alpha chain by a convertase enzyme results in the formation of the C5a anaphylatoxin, which possesses potent spasmogenic and chemotactic activity, and the C5b macromolecular cleavage product, a subunit of the membrane attack complex (MAC). Mutations in this gene cause complement component 5 deficiency, a disease characterized by recurrent bacterial infections. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Nov 2015]
Alternative Names
C5D; C5a; C5b; ECLZB; CPAMD4
